Fredun Pharmaceuticals Limited

Equities

FREDUN6

INE194R01017

Pharmaceuticals

Market Closed - Bombay S.E. 03:00:43 2024-05-18 am EDT 5-day change 1st Jan Change
880.4 INR 0.00% Intraday chart for Fredun Pharmaceuticals Limited +3.08% +1.35%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Fredun Pharmaceuticals Limited Proposes Final Dividend for the Financial Year 2023-24 CI
Fredun Pharmaceuticals' Net Profit Jumps in Fiscal Q4; Shares Dip 9% MT
Fredun Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Fredun Pharmaceuticals Secures Orders from Sea Countries, Expands Product Development in Veterinary Care, and Advances Orthopaedic Applications CI
Fredun Pharmaceuticals Limited Announces Appointment of Ms. Daisy Cyril Dsouza as Additional Independent Director CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Fredun Pharmaceuticals Limited Declared A Dividend At 7% on the Equity Shares of the Company for the Financial Year Ended March 31, 2023 CI
Fredun Pharmaceuticals Limited Proposes Dividend for the Financial Year Ended March 31, 2023 CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Fredun Pharmaceuticals Limited Approves the Resignation of Dr. Chandrakant Shah as Independent Director CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023 CI
Fredun Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2022-23 CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Fredun Pharmaceuticals Limited announced that it has received INR 275.691377 million in funding CI
Fredun Pharmaceuticals Limited Announces Change in Registered Office Address CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022 CI
Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year Ended March 31, 2022 CI
Fredun Pharmaceuticals Limited announced that it expects to receive INR 284.662157 million in funding CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2022 CI
Fredun Pharmaceuticals Limited Approves Dividend for the Financial Year 2021-22 CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022 CI
Fredun Pharmaceuticals Limited Receives Approval for Manufacturing Xenografts for Various Dental and Orthopaedic Surgical Appliances from Central Drugs Standard Control Organisation CI
Fredun Pharmaceuticals Limited Approves Appointment of Jinkal Shah as Company Secretary and Compliance Officer CI
Fredun Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021 CI
Chart Fredun Pharmaceuticals Limited
More charts
Fredun Pharmaceuticals Ltd. is an India-based pharmaceutical company. The Company is primarily engaged in the business of pharmaceuticals and healthcare. The Company operates through four segments: Generics (Exports & Fredun Gx), Pet Healthcare (Freossi), Nutraceuticals (Fredun Nutrition) and Cosmeceuticals (Bird and Beauty or BnB). It offers a range of products, including antihypertensive, antidiabetic, antiretroviral drugs (ARVs) and narcotics. It is also engaged in the manufacturing of dietary /herbal supplements, nutraceuticals, and other healthcare products along with animal healthcare products. The Company primarily exports its products to Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America.
More about the company
  1. Stock Market
  2. Equities
  3. FREDUN6 Stock
  4. News Fredun Pharmaceuticals Limited
  5. Fredun Pharmaceuticals' Net Profit Jumps in Fiscal Q4; Shares Dip 9%
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW